Table 1.
References | Cell type | Animal model | Route of administration | Delivery timing (after ischemia) | Dose | Results |
---|---|---|---|---|---|---|
Asgari Taei et al. (2021) | Human ESC | Rat MCAO | left lateral ventricle | 1, 24, and 48 h | 1 × 106 | Neurological deficits↓ Synaptic↑ Infarct volumes↓ Cerebral edema↓ |
Cheng et al. (2015) | NSC line C17.2 | Rat MCAO | IV (tail vein) | 24 h | 5 × 106 | Functional recovery↑ Neurogenesis↑ proliferation↑ |
Tian et al. (2019) | Leukemia inhibitory factor -transfected NSCs | Rat MCAO | IV (tail vein) | 2 h | 5 × 105 | Lesion volume↓ Functional↑ Glial cell regeneration↑ Apoptosis↓ |
Webb et al. (2018) | NSCs-derived extracellular vesicle | porcine MCAO | IV | 2, 14, and 24 h | 2.7 × 106 | Lesion volume↓ Cerebral diffusivity↑ Motor activity ↑ Exploratory behavior↑ |
Tobin et al. (2020) | interferon-γ–activated BMSCs | Rat MCAO | IV | 4.5 h | 5 × 106/kg | Functional recovery↑ Oligodendrogenesis↑ Microglia activation↓ Inflammation↓ |
Kawabori et al. (2013) | Rat BMSCs | Rat MCAO | ipsilateral striatum | 1 or 4 weeks | 1 × 105 or 1 × 106 | Functional recovery↑ Differentiation ↑ |
Brenneman et al. (2010) | Autologous BMMCs | left MCA and left ICA occlusion | IA (carotid artery) | 24 h | 1 × 107 or 4 × 106 | Neurological recovery↑ Infarct volume↓ Inflammation↓ |
Chang et al. (2013) | Human iPSCs | Rat MCAO | intracerebral | 7 days | 2 × 105 | Behavioral↑ Neurogenesis↑ Inflammation↓ apoptosis↓ |
ESCs, embryonic stem cells; NSCs, neural stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; BMMCs, bone marrow mononuclear cells; iPSCs, induced pluripotent stem cells; MCAO: middle cerebral artery occlusion.